New Triple-Receptor Drug Cuts Body Weight by 28% in Phase III Trial
Retatrutide achieves surgical-level weight loss in 80 weeks, plus key updates on T1D screening, GLP-1 risks, and teen diabetes rates.
Summary
A phase III trial of retatrutide, an investigational triple-receptor agonist from Eli Lilly, showed patients with obesity lost a mean 28% of body weight over 80 weeks, with nearly half losing 30% or more — results typically only seen with bariatric surgery. Separately, a large meta-analysis of 69 trials found calcium and vitamin D supplements offer little benefit for fracture or fall prevention. A German screening study suggests universal type 1 diabetes screening in children may be warranted regardless of family history. Alarming trends include a fourfold rise in type 2 diabetes among adolescents and reports of eating disorder patients using GLP-1 medications. Low-insulinemic diets were linked to less menopausal weight gain.
Detailed Summary
A wave of endocrinology findings is reshaping how clinicians and health-conscious individuals think about weight, diabetes, and hormonal health. The most striking headline involves retatrutide, Eli Lilly's investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In a phase III trial spanning 80 weeks, patients with obesity lost a mean of 28% of their body weight at the 12-mg dose, with nearly half achieving 30% or greater loss — territory previously reserved for bariatric surgery. This positions retatrutide as potentially the most potent pharmacological weight loss agent studied to date.
On the diabetes front, a German screening study published in JAMA found that rates of early-stage type 1 diabetes and progression to clinical disease were similar regardless of family history. This challenges the current practice of screening only genetically at-risk children, suggesting universal pediatric screening could dramatically improve early detection and intervention opportunities before irreversible beta-cell loss occurs.
The adolescent type 2 diabetes picture is equally sobering. Data published in JAMA Pediatrics shows prevalence among 10-to-17-year-olds was nearly fourfold higher in 2022–2024 compared to 2017 estimates, signaling a serious pediatric metabolic health crisis likely driven by diet, sedentary behavior, and obesity trends.
For those interested in supplementation, a systematic review and meta-analysis of 69 randomized trials in The BMJ found that calcium and vitamin D supplements provided little to no benefit in preventing fractures or falls — a finding that challenges widespread supplementation practices among older adults and longevity-focused individuals.
Finally, a prospective cohort study in JAMA Network Open found that low-insulinemic and planetary health diets were associated with less weight gain during menopause, offering dietary strategy insights for women navigating hormonal transitions. Caveats apply throughout: many findings are preliminary, population-specific, or based on observational data requiring further validation.
Key Findings
- Retatrutide achieved 28% mean weight loss over 80 weeks, with ~50% of patients losing 30%+ body weight
- Universal T1D screening in children may be warranted regardless of family history, per JAMA study
- Calcium and vitamin D supplements show little to no benefit for fracture or fall prevention in large meta-analysis
- Type 2 diabetes prevalence in adolescents ages 10–17 is nearly 4x higher than 2017 estimates
- Low-insulinemic diets linked to reduced weight gain during menopause in prospective cohort data
Methodology
This is a news roundup article by MedPage Today synthesizing multiple recent findings from endocrinology. Sources cited include JAMA, JAMA Pediatrics, JAMA Network Open, The BMJ, and NEJM Catalyst — all high-credibility peer-reviewed journals. The retatrutide data comes from an Eli Lilly press announcement of a phase III trial, not yet a full peer-reviewed publication.
Study Limitations
The retatrutide findings are from a company press release, not a peer-reviewed publication, so full safety and efficacy data require scrutiny. The adolescent T2D comparison uses different age ranges across time periods, limiting direct comparison. Several items in this roundup are brief mentions without full study details, requiring readers to consult primary sources.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.